Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComa
PACIFIC PALISADES, Calif.--(BUSINESS WIRE)--Aadi Bioscience, Inc. (Aadi), a privately held clinical stage biopharmaceutical company, today released its independent radiology reviewed data from the nab-sirolimus (ABI-009) registration trial (AMPECT) for Advanced (metastatic or locally advanced) Malignant PEComa (perivascular epithelioid cell tumor) - a rare form of sarcoma for which there is no currently approved therapy. Nanoparticle albumin-bound sirolimus (nab-Sirolimus), an mTOR inhibitor, r